Corbus Pharmaceuticals Announces FDA Orphan Drug Designation and Fast Track Status of Resunab(TM) for the Treatment of Cystic Fibrosis
October 20, 2015 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, MA--(Marketwired - Oct 20, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic,...
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of Resunab(TM) for Treatment of Cystic Fibrosis
October 15, 2015 07:30 ET
|
Corbus Pharmaceuticals Holdings Inc
NORWOOD, MA--(Marketwired - Oct 15, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic,...
Corbus Pharmaceuticals to Present at the 14th Annual BIO Investor Forum
October 13, 2015 07:00 ET
|
Corbus Pharmaceuticals Holdings Inc
NORWOOD, MA--(Marketwired - Oct 13, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic,...
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of Resunab for Systemic Sclerosis
October 07, 2015 07:05 ET
|
Corbus Pharmaceuticals Holdings Inc
NORWOOD, MA--(Marketwired - Oct 7, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and...
Corbus Pharmaceuticals to Present Additional Data on the Effects of Resunab(TM) in the Treatment of Pulmonary Infection and Inflammation in Pre-Clinical Models of Cystic Fibrosis
September 22, 2015 07:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, MA--(Marketwired - Sep 22, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic,...
Corbus Pharmaceuticals Commences Patient Enrollment in Phase 2 Clinical Study of Resunab(TM) for the Treatment of Cystic Fibrosis
September 21, 2015 07:00 ET
|
Corbus Pharmaceuticals Holdings Inc.
NORWOOD, MA--(Marketwired - Sep 21, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and...
Corbus Pharmaceuticals Commences Patient Enrollment in Phase 2 Clinical Study of Resunab(TM) for the Treatment of Systemic Sclerosis
August 31, 2015 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, MA--(Marketwired - Aug 31, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic,...
Corbus Pharmaceuticals Successfully Completes Warrant Call -- Raises $11.3 mm in Total From 100% Exercise of Callable Warrants
August 27, 2015 08:05 ET
|
Corbus Pharmaceuticals Holdings Inc.
NORWOOD, MA--(Marketwired - Aug 27, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and...
Corbus Pharmaceuticals' Investigational Drug Resunab(TM) Granted Fast Track Status by the U.S. FDA for the Treatment of Systemic Sclerosis
August 19, 2015 07:35 ET
|
Corbus Pharmaceuticals Holdings Inc.
NORWOOD, MA--(Marketwired - Aug 19, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and...
Corbus Pharmaceuticals Reports 2015 Second Quarter Financial Results and Provides Business Update
August 13, 2015 07:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, MA--(Marketwired - Aug 13, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and...